Helping investors thrive in an evolving world

With our dynamic perspective and meaningful partnership, we instill investor confidence.

Watch this video to learn how our principles guide us in providing value to our clients and our communities.

View Transcript

Today’s investors want a partner. 

One who can help deliver the solutions, insights, and thought leadershipto help them navigate change, and meet their financial needs. 

Since 1937, T. Rowe Price has been there…guiding clients, seeking to stay ahead of what’s next, and staying true to our purpose…to identify and actively investin opportunities to help people thrivein an evolving world. 

We champion an active, independent approach… with investment professionals working together to uncover opportunities. 

They are guided by curiosity…going out in the field, and asking better questions, to seek better solutions for our clients. 

We pursue performance with principle… balancing risk and opportunity to go after strong long-term investing results, in any market environment. 

We drive deliberate innovation. 

Pioneering solutions in retirement and Target Date investing,active ETFs,investing in the blue economy, and more,to meet clients’ evolving needs. 

And we build meaningful partnerships…with individual investors, financial advisors, retirement plan sponsors, and institutional clients, in more than 50 countries. 

Our commitment to partnership extends to our communities,through direct grants from the T. Rowe Price Foundation,and our associates volunteering tens of thousands of hours each year. 

With our dynamic perspective, and meaningful partnerships,we instill investor confidence. Learn more about how we provide value to our clients, and our communities. 

Visit troweprice.com

View Transcript
Ziad / Health Sciences Imagine that your disease is going to kill you in less than a year, but a company develops a way to genetically engineer your own blood and your own immune cells to actually recognize the cancer and attack it. Instead of poisoning the cancer cells with toxic chemicals that wreak havoc on the immune system, you tweak the patient’s blood and let the body’s natural immune defense take care of the rest. After medical school in the UK, I worked as an emergency room doctor. What drew me to capital allocation in health sciences was the potential to help many people for years to come through investments that help fund medical innovation. My team and I often choose to invest at the very early stages of human trials, and sometimes when it’s just a concept. It’s exciting to see innovations shift from concept to reality. The human body is made up of proteins. Any disease caused by too much of a bad protein can be controlled or cured by blocking protein production at the cellular level. It’s a priority of mine to go out into the field so I can see firsthand if this is something real. Making the right investment decision is important not only for our investors but for mankind in general—because today’s treatment, which took years to develop, can have long-term future benefits for generations to come. Investing lets me use everything I’ve learned as a doctor, to help make a positive impact on the world. So that’s why I go beyond the numbers. Risks: All investments are subject to risks, including the possible loss of principal. Health Science stocks face special risks, including adverse legal or regulatory developments, patent expirations, market competition, and rapidly changing industry dynamics . Important Information This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested. The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction. Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price. The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. Australia - Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. Canada - Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.’s investment management services are only available to Accredited Investors as defined under National Instrument 45-106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services. DIFC - Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd which is regulated by the Dubai Financial Services Authority as a Representative Office. EEA - Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. Hong Kong - Issued by T. Rowe Price Hong Kong Limited, 6/F, Chater House, 8 Connaught Road Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission. New Zealand - Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013. Singapore - Issued by T. Rowe Price Singapore Private Ltd. (UEN: 201021137E), No. 501 Orchard Rd, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and regulated by the Monetary Authority of Singapore. Switzerland - Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. UK - This material is issued and approved by T. Rowe Price International Ltd, 60 Queen Victoria Street, London, EC4N 4TZ which is authorised and regulated by the UK Financial Conduct Authority. USA - Issued in the USA by T. Rowe Price Associates, Inc., and T. Rowe Price Investment Services, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which are regulated by the US Securities and Exchange Commission and Financial Industry Regulatory Authority, Inc., respectively. © 2023 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/ or apart, trademarks of T. Rowe Price Group, Inc. 202309- 3094347
Our emerging markets team has investment professionals from 26 nationalities speaking 28 languages.
Samy Muaddi, CFA® Head of Emerging Markets
Samy Muaddi is a Portfolio Manager in the International Fixed Income Division, focused on emerging markets.
avatar

We put our clients at the center of our best thinking.

Better questions. Better Insights. T. Rowe Price helps you see what’s ahead, what’s most important, and how our investment teams are responding now. 

Latest insights

Nov 2024 • In the Loop

What Trump’s win means for policy, the economy, and markets

Extending tax cuts and an assertive approach on trade policy likely to be areas of focus.

Oct 2024 • From the Field • Article

Ahead of the Curve: Could a 5% 10-year Treasury yield be around the corner?

Higher Treasury yields expected due to fiscal spending and Fed quantitative tightening.
By  Arif Husain
In the Spotlight

The Angle podcast

The Angle podcast brings you sharp insights on the forces shaping financial markets. With dynamic perspectives from the T. Rowe Price global investing team and special guests, curious investors can gain an information edge on today’s evolving market themes. Better questions, better insights. The Angle - only from T. Rowe Price.

Capabilities to meet a full range of investor needs

Asset class figures and retirement percentage shown represent total assets under management of $1.63 trillion as of September 30, 2024. All amounts shown in U.S. dollars and subject to adjustment.

A destination for all our clients

Read Form CRS for important information on our fees and services.

3730622

Important Information

View the methodology of this analysis (PDF)The performance data shown is past performance and is no guarantee of future results. All investments are subject to risk, including the possible loss of principal. Results from other time periods may differ. Active investing may have higher costs than passive investing and may underperform the broad market or passive peers with similar objectives. Passive investing may lag the performance of actively managed peers as holdings are not reallocated based on changes in market conditions or outlooks on specific securities. 

Analysis by T. Rowe Price. Comparable passive funds are (1) mutual funds and exchange-traded funds (ETFs) classified as an "index fund" in the Morningstar Direct database and (2) in the same Morningstar category as the active funds being analyzed. All Active Managers represents the actively managed (non-"index fund") mutual funds and ETFs in the Morningstar Direct database, excluding those managed by T. Rowe Price. The performance of the T. Rowe Price active funds and the All Active Managers funds were compared against the comparable passive funds using 10-year rolling monthly periods from 1/1/04 to 12/31/23. The analysis was conducted at the Morningstar category level analyzing all open-end funds and ETFs within U.S. Morningstar categories where passive funds are present. Oldest share class returns are used for analysis. Money market funds are excluded from the analysis. 87 funds covering 7,603 rolling 10-year periods. 509 funds covering 41,596 rolling 10-year periods.

All data as of 31 December 2022, unless otherwise noted. Firmwide assets under management include assets managed by T. Rowe Price Associates, Inc., and its investment advisory affiliates. All amounts shown in US dollars.

¹ Figure shown is as of September 30, 2024. Subject to adjustment.
² Top Asset Management Firms ranked by total AUM as of March 31, 2024, compiled by ADV Ratings (https://www.advratings.com/top-asset-management-firms)
³ As of 12/31/23. Sway Research, LLC, "The State of the Target-Date Market: 2024."